Induced pluripotent stem cells as a novel cancer vaccine

References

• American Cancer Society. Cancer facts & figures 2016. Atlanta: American Cancer Society; 2016.
   Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34.
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Cancer facts & figures 2019. Atlanta: American Cancer Society; 2019.
   Google Scholar
• Shackleton M, Quintana E, Fearon ER, et al. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell. 2009;138:822–829.
   PubMed Web of Science ®Google Scholar
• Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367:645–648.
   PubMed Web of Science ®Google Scholar
• Dick JE. Stem cell concepts renew cancer research. Blood. 2008;112:4793–4807.
   PubMed Web of Science ®Google Scholar
• Rosen JM, Jordan CT. The increasing complexity of the cancer stem cell paradigm. Science. 2009;324:1670–1673.
   PubMed Web of Science ®Google Scholar
• Li Y, Zeng H, Xu RH, et al. Vaccination with human pluripotent stem cells generates a broad spectrum of immunological and clinical responses against colon cancer. Stem Cells. 2009;27:3103–3111.
   PubMed Web of Science ®Google Scholar
• de Lucas B, Pérez LM, Gálvez BG. Importance and regulation of adult stem cell migration. J Cell Mol Med. 2018;22:746–754.
   PubMed Web of Science ®Google Scholar
• Li S, Li Q. Cancer stem cells and tumor metastasis (review). Int J Oncol. 2014;45:1806–1812.
   Google Scholar
• Jögi A, Vaapil M, Johansson M, et al. Cancer cell differentiation heterogeneity and aggressive behavior in solid tumors. Ups J Med Sci. 2012;112:217–224.
   Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674.
   PubMed Web of Science ®Google Scholar
• Weinberg RA. How cancer arises. Sci Am. 1996;275:62–70.
   PubMed Web of Science ®Google Scholar
• Otto T, Sicinski P. Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer. 2017;17:93–115.
   PubMed Web of Science ®Google Scholar
• Maher CM, Thomas JD, Haas DA, et al. Small-molecule sigma1 modulator induces autophagic degradation of PD-L1. Mol Cancer Res. 2018;16:243–255.
   PubMed Web of Science ®Google Scholar
• Wang L, Gundelach JH, Bram RJ. Cycloheximide promotes paraptosis induced by inhibition of cyclophilins in glioblastoma multiforme. Cell Death Dis. 2017;8:e2807.
   PubMed Web of Science ®Google Scholar
• Yang Y. Cancer immunotherapy: harnessing the immune system to battle cancer. J Clin Invest. 2015;125:3335–3337.
   PubMed Web of Science ®Google Scholar
• Ehrlich P. Über den jetzigen stand der chemotherapie. Berichte der Dtsch Chem Gesellschaft. 1909;42:17–47.
   Google Scholar
• Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology. 2007;121:1–14.
   PubMed Web of Science ®Google Scholar
• Old LJ, Boyse EA. Immunology of experimental tumors. Annu Rev Med. 2003;15:167–186.
   Google Scholar
• Sachamitr P, Hackett S, Fairchild PJ. Induced pluripotent stem cells: challenges and opportunities for cancer immunotherapy. Front Immunol. 2014;5:176.
   PubMed Web of Science ®Google Scholar
• Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res. 1970;13:1–27.
   PubMed Web of Science ®Google Scholar
• Burnet M. Immunological factors in the process of carcinogenesis. Br Med Bull. 1964;20:154–158.
   PubMed Web of Science ®Google Scholar
• Bevan MJ. Minor H antigens introduced on H-2 different stimulating cells cross-react at the cytotoxic T cell level during in vivo priming. J Immunol. 1976;117:2233–2238.
   PubMed Web of Science ®Google Scholar
• Bevan MJ. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J Exp Med. 2004;143:1283–1288.
   Google Scholar
• Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest. 2007;117:1137–1146.
   PubMed Web of Science ®Google Scholar
• Rygaard J, Povlsen CO. The mouse mutant nude does not develop spontaneous tumours an argument against immunological surveillance. Acta Pathol Microbiol Scand Sect B Microbiol Immunol. 1974;82:B: 99–106.
   Google Scholar
• Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 2004;22:329–360.
   PubMed Web of Science ®Google Scholar
• Arteaga CL, Sliwkowski MX, Osborne CK, et al. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2012;9:16–32.
   PubMed Web of Science ®Google Scholar
• Baselga J, Albanell J, Molina MA, et al. Mechanism of action of trastuzumab and scientific update. Semin Oncol. 2001;28:4–11.
   PubMed Web of Science ®Google Scholar
• Bianchini G, Gianni L. The immune system and response to HER2-targeted treatment in breast cancer. Lancet Oncol. 2014;15:e58–68.
   PubMed Web of Science ®Google Scholar
• Luque-Cabal M, García-Teijido P, Fernández-Pérez Y, et al. Mechanisms behind the resistance to trastuzumab in HER2-amplified breast cancer and strategies to overcome It. Clin Med Insights Oncol. 2016;10:21–30.
   PubMed Web of Science ®Google Scholar
• Scott AM, Allison JP, Wolchok JD. Monoclonal antibodies in cancer therapy. Cancer Immun. 2012;12:14.
   PubMedGoogle Scholar
• Sadelain M. CD19 CAR T cells. Cell. 2017;171:1471.
   PubMed Web of Science ®Google Scholar
• Maude SL, Teachey DT, Porter DL, et al. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood. 2015;125:4017–4023.
   PubMed Web of Science ®Google Scholar
• Klapper JA, Downey SG, Smith FO, et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the national cancer institute between 1986 and 2006. Cancer. 2008;113:293–301.
   PubMed Web of Science ®Google Scholar
• Zaidi MR, Merlino G. The two faces of interferon-γ in cancer. Clin Cancer Res. 2011;17:6118–6124.
   PubMed Web of Science ®Google Scholar
• Menaria J, Kitawat S, Verma V. Cancer vaccine: an overview. Sch J Appl Med Sci Sch J App Med Sci. 2013;1:161–171.
   Google Scholar
• Kao JH. Hepatitis B vaccination and prevention of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol. 2015;29:907–917.
   PubMed Web of Science ®Google Scholar
• Kim MN, Han KH, Ahn SH. Prevention of hepatocellular carcinoma: beyond hepatitis B vaccination. Semin Oncol. 2015;42:316–328.
   PubMed Web of Science ®Google Scholar
• Huh WK, Joura EA, Giuliano AR, et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial. Lancet. 2017;390:2143–2159.
   PubMed Web of Science ®Google Scholar
• Kavanagh K, Pollock KG, Cuschieri K, et al. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study. Lancet Infect Dis. 2017;17:1293–1302.
   PubMed Web of Science ®Google Scholar
• Trimble CL, Morrow MP, Kraynyak KA, et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet. 2015;386:2078–2088.
   PubMed Web of Science ®Google Scholar
• Hollingsworth RE, Jansen K. Turning the corner on therapeutic cancer vaccines. Npj Vaccines. 2019;4:7.
   PubMed Web of Science ®Google Scholar
• Nencioni A, Grünebach F, Schmidt SM, et al. The use of dendritic cells in cancer immunotherapy. Crit Rev Oncol Hematol. 2008;65:191–199.
   PubMed Web of Science ®Google Scholar
• Wu A, Oh S, Gharagozlou S, et al. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma. J Immunother. 2007;30:789–797.
   PubMed Web of Science ®Google Scholar
• Old LJ. Cancer vaccines: an overview. Cancer Immun. 2008;8(Suppl 1):1.
   PubMedGoogle Scholar
• Finn OJ. The dawn of vaccines for cancer prevention. Nat Rev Immunol. 2018;18:183–194.
   PubMed Web of Science ®Google Scholar
• Halevy T, Urbach A. Comparing ESC and iPSC—based models for human genetic disorders. J Clin Med. 2014;3:1146–1162.
   PubMedGoogle Scholar
• Narsinh KH, Plews J, Wu JC. Comparison of human induced pluripotent and embryonic stem cells: fraternal or identical twins? Mol Ther. 2011;19:635–638.
   PubMed Web of Science ®Google Scholar
• Robinton DA, Daley GQ. The promise of induced pluripotent stem cells in research and therapy. Nature. 2012;481:295–305.
   PubMed Web of Science ®Google Scholar
• Ebert AD, Kodo K, Liang P, et al. Characterization of the molecular mechanisms underlying increased ischemic damage in the aldehyde dehydrogenase 2 genetic polymorphism using a human induced pluripotent stem cell model system. Sci Transl Med. 2014;6:255ra130.
   PubMed Web of Science ®Google Scholar
• Matsa E, Burridge PW, Wu JC. Human stem cells for modeling heart disease and for drug discovery. Sci Transl Med. 2014;6:239ps6.
   PubMed Web of Science ®Google Scholar
• Schöne G. Untersuchungen über karzinomimmunität bei mäusen. Münch Med Wochenschr. 1906;51:2517–2519.
   Google Scholar
• Wood KJ, Issa F, Hester J. Understanding stem cell immunogenicity in therapeutic applications. Trends Immunol. 2016;37:5–16.
   PubMed Web of Science ®Google Scholar
• Pearl JI, Kean LS, Davis MM, et al. Pluripotent stem cells: immune to the immune system? Sci Transl Med. 2012;4:164ps25.
   PubMed Web of Science ®Google Scholar
• Kim J, Orkin SH. Embryonic stem cell-specific signatures in cancer: insights into genomic regulatory networks and implications for medicine. Genome Med. 2011;3:75.
   PubMed Web of Science ®Google Scholar
• Kim W-T, Ryu CJ. Cancer stem cell surface markers on normal stem cells. BMB Rep. 2017;50:285–298.
   PubMed Web of Science ®Google Scholar
• Ghosh Z, Huang M, Hu S, et al. Dissecting the oncogenic and tumorigenic potential of differentiated human induced pluripotent stem cells and human embryonic stem cells. Cancer Res. 2011;71:5030–5039.
   PubMed Web of Science ®Google Scholar
• De Almeida PE, Meyer EH, Kooreman NG, et al. Transplanted terminally differentiated induced pluripotent stem cells are accepted by immune mechanisms similar to self-tolerance. Nat Commun. 2014;5:3903.
   PubMed Web of Science ®Google Scholar
• Narsinh KH, Sun N, Sanchez-Freire V, et al. Single cell transcriptional profiling reveals heterogeneity of human induced pluripotent stem cells. J Clin Invest. 2011;121:1217–1221.
   PubMed Web of Science ®Google Scholar
• Themeli M, Rivière I, Sadelain M. New cell sources for T cell engineering and adoptive immunotherapy. Cell Stem Cell. 2015;16:357–366.
   PubMed Web of Science ®Google Scholar
• Kitayama S, Zhang R, Liu TY, et al. Cellular adjuvant properties, direct cytotoxicity of re-differentiated Vα24 invariant NKT-like cells from human induced pluripotent stem cells. Stem Cell Reports. 2016;6:213–227.
   PubMed Web of Science ®Google Scholar
• Kitadani J, Ojima T, Iwamoto H, et al. Cancer vaccine therapy using carcinoembryonic antigen - expressing dendritic cells generated from induced pluripotent stem cells. Sci Rep. 2018;8:4569.
   Web of Science ®Google Scholar
• Iwamoto H, Ojima T, Hayata K, et al. Antitumor immune response of dendritic cells (DCs) expressing tumor-associated antigens derived from induced pluripotent stem cells: in comparison to bone marrow-derived DCs. Int J Cancer. 2014;134:332–341.
   PubMed Web of Science ®Google Scholar
• Themeli M, Kloss CC, Ciriello G, et al. Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nat Biotechnol. 2013;31:928–933.
   PubMed Web of Science ®Google Scholar
• Ueda N, Uemura Y, Zhang R, et al. Generation of TCR-expressing innate lymphoid-like helper cells that induce cytotoxic T cell-mediated anti-leukemic cell response. Stem Cell Reports. 2018;10:1935–1946.
   PubMed Web of Science ®Google Scholar
• Iriguchi S, Kaneko S. Toward the development of true “off-the-shelf” synthetic T-cell immunotherapy. Cancer Sci. 2019;110:16–22.
   PubMed Web of Science ®Google Scholar
• Kooreman NG, Kim Y, de Almeida PE, et al. Autologous iPSC-based vaccines elicit anti-tumor responses in vivo. Cell Stem Cell. 2018;22:501–513.e7.
   PubMed Web of Science ®Google Scholar
• Hailemichael Y, Singh M, Overwijk W. Vaccinating with stem cells to stop cancer. Trends Mol Med. 2018;24:524–526.
   PubMed Web of Science ®Google Scholar
• Gilboa E. The promise of cancer vaccines. Nat Rev Cancer. 2004;4:401–411.
   PubMed Web of Science ®Google Scholar
• Liu JKH. Anti-cancer vaccines — a one-hit wonder? Yale J Biol Med. 2014;87:481–489.
   PubMedGoogle Scholar
• Greig SL. Talimogene laherparepvec: first global approval. Drugs. 2016;76:147–154.
   PubMed Web of Science ®Google Scholar
• Eissa IR, Bustos-Villalobos I, Ichinose T, et al. The current status and future prospects of oncolytic viruses in clinical trials against melanoma, glioma, pancreatic, and breast cancers. Cancers (Basel). 2018;10:356.
   Web of Science ®Google Scholar
• Fesnak AD, June CH, Levine BL. Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer. 2016;16:566–581.
   PubMed Web of Science ®Google Scholar
• Ott PA, Hu Z, Keskin DB, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547:217–221.
   PubMed Web of Science ®Google Scholar
• Bonifant CL, Jackson HJ, Brentjens RJ, et al. Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics. 2016;3:16011.
   PubMed Web of Science ®Google Scholar
• Callahan MK, Postow MA, Wolchok JD. Antibodies to stimulate host immunity: lessons from Ipilimumab. Cancer Immunother. 2013;287–307.
   Google Scholar
• Chalan P, di Dalmazi G, Pani F, et al. Thyroid dysfunctions secondary to cancer immunotherapy. J Endocrinol Invest. 2018;41:625–638.
   PubMed Web of Science ®Google Scholar
• Iglesias P. Cancer immunotherapy-induced endocrinopathies: clinical behavior and therapeutic approach. Eur J Intern Med. 2018;47:6–13.
   PubMed Web of Science ®Google Scholar
• Ileana-Dumbrava E, Subbiah V. Autoimmune hypophysitis. Lancet Oncol. 2018;19:e123.
   PubMed Web of Science ®Google Scholar
• Diecke S, Lu J, Lee J, et al. Novel codon-optimized mini-intronic plasmid for efficient, inexpensive, and xeno-free induction of pluripotency. Sci Rep. 2015;5:8081.
   PubMed Web of Science ®Google Scholar
• Lin H, Li Q, Du Q, et al. Integrated generation of induced pluripotent stem cells in a low-cost device. Biomaterials. 2019;189:23–36.
   PubMed Web of Science ®Google Scholar
• Hentze H, Soong PL, Wang ST, et al. Teratoma formation by human embryonic stem cells: evaluation of essential parameters for future safety studies. Stem Cell Res. 2009;2:198–210.
   PubMed Web of Science ®Google Scholar
• Brivanlou AH, Gage FH, Jaenisch R, et al. Setting standards for human embryonic stem cells. Science. 2003;300:913–916.
   PubMed Web of Science ®Google Scholar
• Kindy MS, Yu J, Zhu H, et al. A therapeutic cancer vaccine against GL261 murine glioma. J Transl Med. 2016;14:1.
   PubMed Web of Science ®Google Scholar
• Deuse T, Hu X, Gravina A, et al. Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients. Nat Biotechnol. 2019;37:252–258.
   PubMed Web of Science ®Google Scholar